Catalog No.
DHE84601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
GPC3, MXR7, GTR2-2, Glypican-3, Intestinal protein OCI-5, OCI5
Concentration
1.1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P51654
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
GC33, RG7686, RO5137382, CAS: 1365267-33-9
Clone ID
Codrituzumab
I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma, PMID: 29508107
Glypican 3-Targeted Therapy in Hepatocellular Carcinoma, PMID: 31510063
Case-control Indian buffet process identifies biomarkers of response to Codrituzumab, PMID: 30922327
Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma, PMID: 29381229
Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab, PMID: 29535817
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC), PMID: 28120036
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma, PMID: 27085251
Heparan sulfate proteoglycans as targets for cancer therapy: a review, PMID: 33180600
Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma, PMID: 33374953
Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis, PMID: 31528232
Glypican-3 is a key tuner of the Hedgehog pathway in COPD., PMID:39844999
Glypican-3 deficiency in liver cancer upregulates MAPK/ERK pathway but decreases cell proliferation., PMID:39113871
H2BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy., PMID:35670495
Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma., PMID:33374953
Heparan sulfate proteoglycans as targets for cancer therapy: a review., PMID:33180600
Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis., PMID:31528232
Glypican 3-Targeted Therapy in Hepatocellular Carcinoma., PMID:31510063
Case-control Indian buffet process identifies biomarkers of response to Codrituzumab., PMID:30922327
Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab., PMID:29535817
I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma., PMID:29508107
Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma., PMID:29381229
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)., PMID:28120036
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma., PMID:27085251
For research use only. Not for human or drug use.
